Compare HURN & RARE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HURN | RARE |
|---|---|---|
| Founded | 2002 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Professional Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.8B | 2.3B |
| IPO Year | 2004 | 2014 |
| Metric | HURN | RARE |
|---|---|---|
| Price | $177.47 | $22.60 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 19 |
| Target Price | ★ $215.50 | $73.11 |
| AVG Volume (30 Days) | 145.5K | ★ 4.0M |
| Earning Date | 02-24-2026 | 02-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 32.32 | N/A |
| EPS | ★ 5.98 | N/A |
| Revenue | ★ $1,618,977,000.00 | $630,598,000.00 |
| Revenue This Year | $14.19 | $19.68 |
| Revenue Next Year | $9.49 | $19.44 |
| P/E Ratio | $29.87 | ★ N/A |
| Revenue Growth | 12.67 | ★ 20.63 |
| 52 Week Low | $120.25 | $18.41 |
| 52 Week High | $186.78 | $46.50 |
| Indicator | HURN | RARE |
|---|---|---|
| Relative Strength Index (RSI) | 46.93 | 34.75 |
| Support Level | $179.53 | $22.00 |
| Resistance Level | $186.59 | $24.65 |
| Average True Range (ATR) | 5.42 | 1.28 |
| MACD | -0.66 | 0.08 |
| Stochastic Oscillator | 39.82 | 22.33 |
Huron Consulting Group Inc is a professional services firm. The company provides expertise in technology, operations, advisory services, & analytics through three operating segments namely Healthcare, Education, and Commercial. Healthcare segment helps the firms to transform and innovate the delivery model to focus on patient wellness by improving quality outcomes, minimizing care variation and fundamentally improving patient and population health, Education segment provides management consulting and technology solutions, and Commercial segment is focused on serving industries and organizations facing disruption and regulatory change. It generates a majority of its revenue from the Healthcare Segment.
Ultragenyx Pharmaceutical Inc is a USA-based biopharmaceutical company. It identifies, acquires, develops, and commercializes novel products for the treatment of serious rare and ultra-rare diseases, with a focus on serious, debilitating genetic diseases. The company's medicine portfolio includes Crysvita, Dojolvi and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients 1 year of age and older. Mepsevii is indicated in pediatric and adult patients for the treatment of Mucopolysaccharidosis VII.